lancet-header

Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.

Mortality Rate of Lymphoma in China, 2013-2020

24 Pages Posted: 8 Nov 2021

See all articles by Weiping Liu

Weiping Liu

Peking University - Key Laboratory of Carcinogenesis and Translational Research

Jinlei Qi

Collaborative Innovation Center for Diagnosis Treatment of Infectious Diseases - National Center for Chronic and Noncommunicable Disease Control and Prevention

Jiangmei Liu

Collaborative Innovation Center for Diagnosis Treatment of Infectious Diseases - National Center for Chronic and Noncommunicable Disease Control and Prevention

Yuqin Song

Peking University - Key Laboratory of Carcinogenesis and Translational Research

Lijun Wang

Collaborative Innovation Center for Diagnosis Treatment of Infectious Diseases - National Center for Chronic and Noncommunicable Disease Control and Prevention

Maigeng Zhou

Collaborative Innovation Center for Diagnosis Treatment of Infectious Diseases - National Center for Chronic and Noncommunicable Disease Control and Prevention

Jun Ma

Harbin Institute of Hematology & Oncology

Zhu Jun

Peking University - Key Laboratory of Carcinogenesis and Translational Research

Union for China Leukemia Investigators of the Chinese Society of Clinical Oncology

Union for China Lymphoma Investigators of the Chinese Society of Clinical Oncology

More...

Abstract

Background: Lymphoma is a malignant disease that threatens human health and imposes a significant burden on the society burden; however, there are limited accurate mortality data on lymphoma in China.

Methods: Mortality data of patients with lymphoma were extracted from the disease surveillance system of the Chinese Center for Disease Control and Prevention. Mortality was represented by the number of deaths, crude death rate, and age-standardized mortality rate. Temporal trends in mortality rates were examined using the fitting joinpoint models.

Findings: Lymphoma accounted for 31,225 deaths in 2020, of which 1,838 and 29,387 were due to Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), respectively. The age-standardized mortality rate per 100,000 population was 1·76 for lymphoma, 0·10 for HL, and 1·65 for NHL. The mortality rate increased with age, reaching a peak in the age group of 80–84 years for HL and over 85 years for NHL. Moreover, the death risk due to lymphoma was approximately 1·5–2 times greater in males than in females in all age groups. The mortality rate was higher in eastern China than in central and western China, indicating a heterogeneous distribution at the provincial level. During 2013–2020, the mortality rate of lymphoma decreased by 1·85% (−22·94% for HL and −0·14% for NHL).

Interpretation: The mortality rate of lymphoma varied by sex, age, and region (provinces). A significant decrease in the mortality rate of HL was demonstrated. This highlights the need to establish a differentiated strategy for disease control and prevention.

Funding Information: None.

Declaration of Interests: We declare no competing interests.

Keywords: Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Epidemiology, Mortality

Suggested Citation

Liu, Weiping and Qi, Jinlei and Liu, Jiangmei and Song, Yuqin and Wang, Lijun and Zhou, Maigeng and Ma, Jun and Jun, Zhu and Oncology, Union for China Leukemia Investigators of the Chinese Society of Clinical and Oncology, Union for China Lymphoma Investigators of the Chinese Society of Clinical, Mortality Rate of Lymphoma in China, 2013-2020. Available at SSRN: https://ssrn.com/abstract=3958923 or http://dx.doi.org/10.2139/ssrn.3958923

Weiping Liu

Peking University - Key Laboratory of Carcinogenesis and Translational Research ( email )

No. 38 Xueyuan Road
Haidian District
Beijing, Beijing 100871
China

Jinlei Qi

Collaborative Innovation Center for Diagnosis Treatment of Infectious Diseases - National Center for Chronic and Noncommunicable Disease Control and Prevention ( email )

Beijing 100050
China

Jiangmei Liu

Collaborative Innovation Center for Diagnosis Treatment of Infectious Diseases - National Center for Chronic and Noncommunicable Disease Control and Prevention ( email )

Beijing 100050
China

Yuqin Song

Peking University - Key Laboratory of Carcinogenesis and Translational Research ( email )

No. 38 Xueyuan Road
Haidian District
Beijing, Beijing 100871
China

Lijun Wang

Collaborative Innovation Center for Diagnosis Treatment of Infectious Diseases - National Center for Chronic and Noncommunicable Disease Control and Prevention ( email )

Beijing 100050
China

Maigeng Zhou (Contact Author)

Collaborative Innovation Center for Diagnosis Treatment of Infectious Diseases - National Center for Chronic and Noncommunicable Disease Control and Prevention ( email )

Beijing 100050
China
86 10 63040442 (Phone)

Jun Ma

Harbin Institute of Hematology & Oncology ( email )

Harbin
China
86 0451 84694406 (Phone)

Zhu Jun

Peking University - Key Laboratory of Carcinogenesis and Translational Research ( email )

No. 38 Xueyuan Road
Haidian District
Beijing, Beijing 100871
China

Click here to go to TheLancet.com

Paper statistics

Abstract Views
53
Downloads
4
PlumX Metrics